NSCI — Nanalysis Scientific Balance Sheet
0.000.00%
- CA$21.24m
- CA$38.54m
- CA$45.50m
- 53
- 41
- 14
- 27
Annual balance sheet for Nanalysis Scientific, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 3.16 | 10.4 | 3.52 | 0.759 | 1.38 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3.04 | 6.1 | 8.98 | 9.76 | 11.1 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 9.35 | 20.8 | 22 | 17.9 | 18.3 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.95 | 2.54 | 6.42 | 4.74 | 2.89 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 24 | 37.8 | 69.9 | 53.8 | 42.4 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 6.3 | 8.65 | 13.5 | 14.6 | 14.4 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 9.64 | 13.8 | 34.8 | 30.3 | 26.8 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 14.3 | 24 | 35.1 | 23.5 | 15.5 |
| Total Liabilities & Shareholders' Equity | 24 | 37.8 | 69.9 | 53.8 | 42.4 |
| Total Common Shares Outstanding |